A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy Using Combinations of Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol GS US 256 0124).
Phase of Trial: Phase II
Latest Information Update: 26 Apr 2015
At a glance
- Drugs Ledipasvir (Primary) ; Vedroprevir (Primary) ; Peginterferon alfa-2a; Ribavirin; Tegobuvir
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 14 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClincialTrials.gov record.
- 01 Oct 2012 Planned end date changed from 1 Jul 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
- 05 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.